Vertex Reports Third Quarter 2026 Financial Results
Stocks in this Quantisnow insightHealth Care
Quantisnow AI summary
Q3 revenue $3.44B, up 12% y/y; FY26 revenue guidance raised to $13.15B-$13.25B, though GAAP net income fell to $654M.
Historical context for VRTX
Across the 28 sessions after earlier VRTX headlines, the stock closed higher 17 times and lower 11 times, with a median move of 1.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VRTX | SPY |
|---|---|---|---|
| Oct 23, 2026 | Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026 | -2.1% | -0.5% |
| Oct 21, 2026 | Vertex Appoints Daniel Brennan to its Board of Directors | +1.9% | +0.5% |
| Oct 9, 2026 | Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference | +1.4% | +0.6% |
| Oct 8, 2026 | Vertex to Announce Third Quarter 2026 Financial Results November 2nd | -0.5% | -0.4% |
| Sep 22, 2026 | Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial | +0.8% | -0.0% |
| Sep 21, 2026 | Leerink Partners initiated coverage on Vertex Pharma with a new price target | +0.5% | +1.6% |
Quantisnow market dataNASDAQ
VRTX
Vertex Pharmaceuticals Incorporated
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 1991
Get push alerts for VRTX
Full VRTX profile on Quantisnow Follow VRTX and get a push notification the moment its next story breaks.